News - Abraxane, North America


Current filters:

AbraxaneNorth America

Popular Filters

US FDA backs Abraxane for metastatic pancreatic cancer


US biotech firm Celgene (Nasdaq: CELG) said on Friday (September 6) that the US Food and Drug Administration…

AbraxaneBiotechnologyCelgenegemcitabine HclNorth AmericaOncologyRegulation

Pivotal drivers for prescribing metastatic pancreatic cancer drugs: report


The effect on key efficacy endpoints, primarily the effect of an emerging therapy on overall survival,…

AbraxaneBiotechnologyCelgeneEli LillyEuropeGemzarMarkets & MarketingNorth AmericaOncologyOnconova TherapeuticsPharmaceuticalrigosertib

FDA Approves Abraxane for NSCLC and expands indication for Actemra


The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Abraxane…

AbraxaneActemraAnti-Arthritics/RheumaticsBiotechnologyCelgeneGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

Back to top